Cutaneous leishmaniasis affects 0.7 to 1.7 million people globally and an effective medicine is needed. Our aim is to develop ex vivo skin infection models to increase understanding of the infected skin, and to inform the development of novel topical medicines. The first part of the project will investigate the changes in skin upon infection. The second part of the project will measure the ability of formulations to enhance drug permeation into the skin, entry into target cells and compartments, and killing of parasites. Ex vivo- in vivo correlations will be explored and used to improve the ex vivo models.
Alvar, J., et al., Leishmaniasis Worldwide and Global Estimates of Its Incidence. Plos One, 2012. 7(5).
Croft, S.L. and P. Olliaro, Leishmaniasis chemotherapy-challenges and opportunities. Clinical Microbiology and Infection, 2011. 17(10): p. 1478-1483.
Rubinchik, E. and C. Pasetka, Ex Vivo Skin Infection Model, in Antimicrobial Peptides: Methods and Protocols, A. Giuliani and A.C. Rinaldi, Editors. 2010. p. 359-369.
Goetz, C., et al., Xenobiotic metabolism capacities of human skin in comparison with a 3D epidermis model and keratinocyte-based cell culture as in vitro alternatives for chemical testing: activating enzymes (Phase I). Experimental Dermatology, 2012. 21(5): p. 358-363
Walochnik, J., et al., Anti-Acanthamoeba efficacy and toxicity of miltefosine in an organotypic skin equivalent. Journal of Antimicrobial Chemotherapy, 2009. 64(3): p. 539-545.